A2A Pharmaceuticals

A2A Pharmaceuticals is a small biopharmaceutical company based in New York, New York. With a team of 3 employees, the company focuses on developing innovative treatments for challenging medical conditions. A2A Pharmaceuticals specializes in designing computationally optimized small molecule therapeutics for cancer and antibiotic-resistant bacterial infections. Their oncology programs target essential protein-protein interactions in leukemia and various solid tumors. Their antibiotic programs concentrate on biosynthetic enzymes in gram-negative bacteria, utilizing pathways not found in humans. The company's proprietary SCULPT platform is the foundation of their drug development process. This unique approach integrates computational tools and experimental data to design new drug candidates. The process involves constructing combinatorial in silico libraries of thousands to millions of small molecules, iteratively evaluating them for potency and optimal ADMET properties, ultimately leading to the selection of the most promising candidates. For inquiries or further information, please visit A2A Pharmaceuticals' website at a2apharma.com.